[go: up one dir, main page]

MX2018004302A - Acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxil ico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adiccion y carcinoma hepatocelular. - Google Patents

Acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxil ico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adiccion y carcinoma hepatocelular.

Info

Publication number
MX2018004302A
MX2018004302A MX2018004302A MX2018004302A MX2018004302A MX 2018004302 A MX2018004302 A MX 2018004302A MX 2018004302 A MX2018004302 A MX 2018004302A MX 2018004302 A MX2018004302 A MX 2018004302A MX 2018004302 A MX2018004302 A MX 2018004302A
Authority
MX
Mexico
Prior art keywords
gaba
treatment
difluorometilenyl
ciclopent
carcinomar
Prior art date
Application number
MX2018004302A
Other languages
English (en)
Other versions
MX380592B (es
Inventor
Takaya Kenji
B Silverman Richard
V Le Hoang
I Juncosa Jose
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of MX2018004302A publication Critical patent/MX2018004302A/es
Publication of MX380592B publication Critical patent/MX380592B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos relacionados con el ciclopenteno carboxílico como inhibidores GABA-AT para el tratamiento de diversas adicciones, trastornos y estados patológicos.
MX2018004302A 2015-10-09 2016-10-10 Ácido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular. MX380592B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239330P 2015-10-09 2015-10-09
PCT/US2016/056245 WO2017062942A2 (en) 2015-10-09 2016-10-10 (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
MX2018004302A true MX2018004302A (es) 2018-11-09
MX380592B MX380592B (es) 2025-03-12

Family

ID=58488679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004302A MX380592B (es) 2015-10-09 2016-10-10 Ácido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular.

Country Status (20)

Country Link
US (3) US9670141B2 (es)
EP (1) EP3341355B1 (es)
JP (1) JP6841821B2 (es)
KR (1) KR102745965B1 (es)
CN (1) CN108137484B (es)
AU (1) AU2016334396B2 (es)
BR (1) BR112018007026B1 (es)
CA (1) CA3001330A1 (es)
CL (1) CL2018000914A1 (es)
CO (1) CO2018003828A2 (es)
DK (1) DK3341355T3 (es)
ES (1) ES2825349T3 (es)
HU (1) HUE053429T2 (es)
IL (1) IL258516A (es)
LT (1) LT3341355T (es)
MX (1) MX380592B (es)
PE (1) PE20190349A1 (es)
PL (1) PL3341355T3 (es)
PT (1) PT3341355T (es)
WO (1) WO2017062942A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3183254T (pt) 2014-08-21 2019-08-29 Boehringer Ingelheim Int Novos compostos de espiro[3h-indole-3,2¿-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
PL3341355T3 (pl) * 2015-10-09 2021-03-08 Northwestern University Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowego
SI3359542T1 (sl) 2015-10-09 2021-08-31 Boehringer Ingelheim International Gmbh Spojine in derivati spiro(3H-indol-3,2'-pirolidin)-2(1H)-ona kot MDM2-P53 inhibitorji
KR20240110989A (ko) 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들
US10653652B2 (en) 2018-02-08 2020-05-19 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
US11771671B2 (en) * 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
CN112218628A (zh) * 2018-03-29 2021-01-12 奥维德医疗公司 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途
US10822301B2 (en) 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
US10836708B2 (en) * 2018-05-25 2020-11-17 Northwestern University Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid
JP7387179B2 (ja) 2018-06-07 2023-11-28 オービッド・セラピューティクス・インコーポレイテッド 発達障害の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸および関連化合物、（１ｓ，３ｓ）－３－アミノ－４－（ジフルオロメチリデン）シクロペンタン－１－カルボン酸ならびにビガバトリンの使用
WO2020176511A1 (en) 2019-02-25 2020-09-03 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene) cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
WO2020206234A1 (en) 2019-04-03 2020-10-08 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
CN110935495B (zh) * 2019-11-29 2021-02-23 中国科学院电子学研究所 Gaba和电生理微纳同步传感检测芯片及其制备方法
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
CN117321025A (zh) * 2021-03-03 2023-12-29 西北大学 作为人鸟氨酸氨基转移酶的选择性灭活剂的(s)-3-氨基-4,4-二卤代环戊-1-烯甲酸
EP4551205A4 (en) * 2022-07-06 2025-11-12 Ovid Therapeutics Inc USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN CANCER TREATMENT
KR20250149771A (ko) * 2023-02-17 2025-10-16 오비드 테라퓨틱스 인크. 위장관 장애의 치료 및 면역조절제로서의 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
KR20250145688A (ko) * 2023-02-17 2025-10-13 오비드 테라퓨틱스 인크. 당뇨병 및 당뇨 전단계의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
US20240285563A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis
AU2024220869A1 (en) * 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
IL177609A (en) 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma
EP2542234A4 (en) * 2010-02-25 2013-07-31 Univ Northwestern PROCESS FOR USE OF (1S, 3S -) - 3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANIC ACID
AR087700A1 (es) * 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
PL3341355T3 (pl) * 2015-10-09 2021-03-08 Northwestern University Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowego

Also Published As

Publication number Publication date
US20170239202A1 (en) 2017-08-24
CN108137484B (zh) 2021-02-12
US9993449B2 (en) 2018-06-12
PL3341355T3 (pl) 2021-03-08
CN108137484A (zh) 2018-06-08
HUE053429T2 (hu) 2021-07-28
AU2016334396A1 (en) 2018-04-19
IL258516A (en) 2018-05-31
US20180271816A1 (en) 2018-09-27
US9670141B2 (en) 2017-06-06
BR112018007026A2 (pt) 2018-10-16
WO2017062942A3 (en) 2018-03-01
BR112018007026B1 (pt) 2022-06-21
AU2016334396B2 (en) 2021-04-08
MX380592B (es) 2025-03-12
US20170101364A1 (en) 2017-04-13
PE20190349A1 (es) 2019-03-07
EP3341355A2 (en) 2018-07-04
HK1253002A1 (zh) 2019-06-06
PT3341355T (pt) 2020-10-21
LT3341355T (lt) 2020-11-10
KR102745965B1 (ko) 2024-12-20
EP3341355A4 (en) 2019-04-10
CA3001330A1 (en) 2017-04-13
CO2018003828A2 (es) 2018-07-19
ES2825349T3 (es) 2021-05-17
EP3341355B1 (en) 2020-09-30
JP6841821B2 (ja) 2021-03-10
JP2018531941A (ja) 2018-11-01
KR20180052782A (ko) 2018-05-18
WO2017062942A2 (en) 2017-04-13
DK3341355T3 (da) 2020-10-26
CL2018000914A1 (es) 2018-08-31

Similar Documents

Publication Publication Date Title
MX2018004302A (es) Acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxil ico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adiccion y carcinoma hepatocelular.
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
GT201700035A (es) Compuestos aminopirimidinilo como inhibidores de jak
IL256209A (en) Novel cannabinoid combination therapies for multiple myeloma (mm)
LT3261640T (lt) 5ht agonistai epilepsijos sutrikimų gydymui
MX375467B (es) Proceso para la preparacion de un compuesto de diariltiohidantoina.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX385914B (es) Método para tratar un tumor cerebral
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
FR3031114B1 (fr) Procede de production de chitine par hydrolyse enzymatique avec traitement prealable avec un agent oxydant
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
PT2974822T (pt) Método de divisão de substratos semicondutores finos
EP3356033A4 (en) METHOD FOR THE CATALYTIC HYDROGENATION OF HALONITROAROMATES
MX383748B (es) Procesos para la preparación de un compuesto de diariltiohidantoína.
BR112017009289A2 (pt) métodos de administrar composições de amantadina
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
HUE044577T2 (hu) Eljárás karbamid elõállítására
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
EP3311767A4 (en) HIGH FREQUENCY TREATMENT TOOL
PL3271322T3 (pl) Proces oczyszczania kwasu monochloroacetycznego
MX376191B (es) Composicion hiperosmolar de acido hialuronico.
DK3615023T3 (da) Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade
MX2019006143A (es) Metodos de administracion de tratamiento antifibrotico.
LT3482761T (lt) Kompozicijos, apimančios kromoglicino rūgštį, skirtos dermatito gydymui
CL2016002925A1 (es) Procedimiento mejorado para preparar ácidos crotónicos sustituidos